Shandong Buchang Pharmaceuticals Co Ltd (603858.SS) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · China · ISIN CNE100002FV6
Shandong Buchang Pharmaceuticals Co Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 11.01 bn CNY | 11.88 bn CNY |
| Gross profit | 6.45 bn CNY | 7.48 bn CNY |
| Operating income | -246.75 m CNY | 1.48 bn CNY |
| EBIT | 680.71 m CNY | 652.66 m CNY |
| Net income | -553.80 m CNY | 360.78 m CNY |
| Diluted EPS – continuing operations | -0.51 CNY | 0.34 CNY |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Shandong Buchang Pharmaceuticals Co Ltd
Shandong Buchang Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicines in China and internationally. It offers medicines to treat cardiac and cerebral vascular, urinary and digestive, respiratory, gynecological, and other diseases, as well as diabetes. The company was founded in 1993 and is based in Heze, China.
More stocks
- Shanghai Kingstar Winning Software (300253.SZ)
- Yunnan Shennong Agricultural Industry Group Co Ltd (605296.SS)
- Hubei DOTI Micro Technology Co. Ltd. (301183.SZ)
- MLS Co Ltd (002745.SZ)
- Suzhou Nanomicro Technology Co Ltd (688690.SS)
- Fortrea Holdings Inc. (FTRE)
- LiveRamp Holdings, Inc. (RAMP)
- Mitsui E&S Co Ltd (7003.T)
- Dermapharm Holding (DMP.DE)
- Anhui XDLK Microsystem Corp. Ltd. A (688582.SS)
- NETLIST INC (NLST)
- NV Bekaert SA (BEKB.BR)
Not investment advice. All data without warranty, price as of 23.10.2026. Details in the risk notice.